메뉴 건너뛰기




Volumn 61, Issue 2, 2016, Pages 358-370

Budesonide Multi-matrix for the Treatment of Patients with Ulcerative Colitis

Author keywords

Budesonide MMX; Induction therapy; Remission; Ulcerative colitis

Indexed keywords

BUDESONIDE; CORTICOSTEROID; HYDROCORTISONE; MESALAZINE; PLACEBO; PREDNISOLONE; ANTIINFLAMMATORY AGENT; DELAYED RELEASE FORMULATION; DRUG DOSAGE FORM;

EID: 84946426642     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-015-3897-0     Document Type: Review
Times cited : (33)

References (59)
  • 2
    • 83755219473 scopus 로고    scopus 로고
    • Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review
    • PID: 22001864
    • Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46–54.
    • (2012) Gastroenterology , vol.142 , pp. 46-54
    • Molodecky, N.A.1    Soon, I.S.2    Rabi, D.M.3
  • 3
    • 84903462965 scopus 로고    scopus 로고
    • Mucosal healing as a target of therapy for colonic inflammatory bowel disease and methods to score disease activity
    • PID: 24975528
    • Walsh A, Palmer R, Travis S. Mucosal healing as a target of therapy for colonic inflammatory bowel disease and methods to score disease activity. Gastrointest Endosc Clin N Am. 2014;24:367–378.
    • (2014) Gastrointest Endosc Clin N Am , vol.24 , pp. 367-378
    • Walsh, A.1    Palmer, R.2    Travis, S.3
  • 5
    • 84879441620 scopus 로고    scopus 로고
    • Health-related quality of life in patients with inflammatory bowel disease: a single-center experience
    • PID: 24714279
    • Kalafateli M, Triantos C, Theocharis G, et al. Health-related quality of life in patients with inflammatory bowel disease: a single-center experience. Ann Gastroenterol. 2013;26:243–248.
    • (2013) Ann Gastroenterol , vol.26 , pp. 243-248
    • Kalafateli, M.1    Triantos, C.2    Theocharis, G.3
  • 6
    • 33751574430 scopus 로고    scopus 로고
    • A practical perspective on ulcerative colitis: patients’ needs from aminosalicylate therapies
    • PID: 17119384
    • Loftus EV Jr. A practical perspective on ulcerative colitis: patients’ needs from aminosalicylate therapies. Inflamm Bowel Dis. 2006;12:1107–1113.
    • (2006) Inflamm Bowel Dis , vol.12 , pp. 1107-1113
    • Loftus, E.V.1
  • 9
    • 84869089859 scopus 로고    scopus 로고
    • Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management
    • PID: 23040451
    • Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis. 2012;6:991–1030.
    • (2012) J Crohns Colitis , vol.6 , pp. 991-1030
    • Dignass, A.1    Lindsay, J.O.2    Sturm, A.3
  • 10
    • 84898853766 scopus 로고    scopus 로고
    • Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis
    • COI: 1:CAS:528:DC%2BC2cXmsFaisrs%3D, PID: 24641622
    • Danese S, Siegel CA, Peyrin-Biroulet L. Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis. Aliment Pharmacol Ther. 2014;39:1095–1103.
    • (2014) Aliment Pharmacol Ther , vol.39 , pp. 1095-1103
    • Danese, S.1    Siegel, C.A.2    Peyrin-Biroulet, L.3
  • 11
    • 44949242296 scopus 로고    scopus 로고
    • Immunosuppressant medications and mortality in inflammatory bowel disease
    • COI: 1:CAS:528:DC%2BD1cXos1WrtLs%3D, PID: 18494836
    • Lewis JD, Gelfand JM, Troxel AB, et al. Immunosuppressant medications and mortality in inflammatory bowel disease. Am J Gastroenterol. 2008;103:1428–1435.
    • (2008) Am J Gastroenterol , vol.103 , pp. 1428-1435
    • Lewis, J.D.1    Gelfand, J.M.2    Troxel, A.B.3
  • 12
    • 33646147141 scopus 로고    scopus 로고
    • Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry
    • COI: 1:CAS:528:DC%2BD28XlsVeqs7s%3D, PID: 16678077
    • Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4:621–630.
    • (2006) Clin Gastroenterol Hepatol , vol.4 , pp. 621-630
    • Lichtenstein, G.R.1    Feagan, B.G.2    Cohen, R.D.3
  • 13
    • 0344074455 scopus 로고    scopus 로고
    • Binding kinetics of budesonide to the human glucocorticoid receptor
    • COI: 1:CAS:528:DyaK1cXjt1Cmtrc%3D, PID: 9795066
    • Esmailpour N, Högger P, Rohdewald P. Binding kinetics of budesonide to the human glucocorticoid receptor. Eur J Pharm Sci. 1998;6:219–223.
    • (1998) Eur J Pharm Sci , vol.6 , pp. 219-223
    • Esmailpour, N.1    Högger, P.2    Rohdewald, P.3
  • 14
    • 0025690782 scopus 로고
    • Overview of newer glucocorticosteroid preparations for inflammatory bowel disease
    • Brattsand R. Overview of newer glucocorticosteroid preparations for inflammatory bowel disease. Can J Gastroenterol. 1990;4:407–414.
    • (1990) Can J Gastroenterol , vol.4 , pp. 407-414
    • Brattsand, R.1
  • 15
    • 84868127664 scopus 로고    scopus 로고
    • ® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study
    • COI: 1:CAS:528:DC%2BC38XhtlOnsLrN, PID: 22892337
    • ® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology. 2012;143:1218–1226.
    • (2012) Gastroenterology , vol.143 , pp. 1218-1226
    • Sandborn, W.J.1    Travis, S.2    Moro, L.3
  • 16
    • 84893767519 scopus 로고    scopus 로고
    • Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study
    • COI: 1:CAS:528:DC%2BC2cXmslWltLc%3D, PID: 23436336
    • Travis SP, Danese S, Kupcinskas L, et al. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut. 2014;63:433–441.
    • (2014) Gut , vol.63 , pp. 433-441
    • Travis, S.P.1    Danese, S.2    Kupcinskas, L.3
  • 17
    • 84866746316 scopus 로고    scopus 로고
    • ® 6 mg QD for the maintenance of remission in patients with ulcerative colitis: results from a phase III, 12 month safety and extended use study [Abstract Su2080]
    • ® 6 mg QD for the maintenance of remission in patients with ulcerative colitis: results from a phase III, 12 month safety and extended use study [Abstract Su2080]. Gastroenterology. 2012;142:S-564.
    • (2012) Gastroenterology , vol.142 , pp. S-564
    • Sandborn, W.J.1    Danese, S.2    Ballard, E.D.3
  • 18
    • 0030045968 scopus 로고    scopus 로고
    • Oral budesonide as maintenance treatment for Crohn’s disease: a placebo-controlled, dose-ranging study
    • COI: 1:CAS:528:DyaK28XhtFKitLw%3D, PID: 8536887
    • Greenberg GR, Feagan BG, Martin F, The Canadian Inflammatory Bowel Disease Study Group, et al. Oral budesonide as maintenance treatment for Crohn’s disease: a placebo-controlled, dose-ranging study. Gastroenterology. 1996;110:45–51.
    • (1996) Gastroenterology , vol.110 , pp. 45-51
    • Greenberg, G.R.1    Feagan, B.G.2    Martin, F.3    The Canadian Inflammatory Bowel Disease Study Group4
  • 20
    • 7144264393 scopus 로고    scopus 로고
    • Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn’s disease
    • COI: 1:CAS:528:DyaK1cXivFSlt7k%3D, PID: 9616309
    • Gross V, Andus T, Ecker KW, The Budesonide Study Group, et al. Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn’s disease. Gut. 1998;42:493–496.
    • (1998) Gut , vol.42 , pp. 493-496
    • Gross, V.1    Andus, T.2    Ecker, K.W.3    The Budesonide Study Group4
  • 21
    • 0033033651 scopus 로고    scopus 로고
    • Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn’s disease: a multicentre randomized placebo-controlled trial
    • COI: 1:CAS:528:DC%2BD3cXptFeltg%3D%3D, PID: 10333200
    • Ewe K, Bottger T, Buhr HJ, Ecker KW, Otto HF, The German Budesonide Study Group. Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn’s disease: a multicentre randomized placebo-controlled trial. Eur J Gastroenterol Hepatol. 1999;11:277–282.
    • (1999) Eur J Gastroenterol Hepatol , vol.11 , pp. 277-282
    • Ewe, K.1    Bottger, T.2    Buhr, H.J.3    Ecker, K.W.4    Otto, H.F.5    The German Budesonide Study Group6
  • 22
    • 0032900233 scopus 로고    scopus 로고
    • Oral budesonide for prevention of postsurgical recurrence in Crohn’s disease
    • COI: 1:CAS:528:DyaK1MXht1CgsLc%3D, PID: 9922309
    • Hellers G, Cortot A, Jewell D, The IOIBD Budesonide Study Group, et al. Oral budesonide for prevention of postsurgical recurrence in Crohn’s disease. Gastroenterology. 1999;116:294–300.
    • (1999) Gastroenterology , vol.116 , pp. 294-300
    • Hellers, G.1    Cortot, A.2    Jewell, D.3    The IOIBD Budesonide Study Group4
  • 23
    • 14644417773 scopus 로고    scopus 로고
    • Budesonide as maintenance treatment in Crohn’s disease: a placebo-controlled trial
    • COI: 1:CAS:528:DC%2BD2MXisFCrsb8%3D, PID: 15709986
    • Hanauer S, Sandborn WJ, Persson A, Persson T. Budesonide as maintenance treatment in Crohn’s disease: a placebo-controlled trial. Aliment Pharmacol Ther. 2005;21:363–371.
    • (2005) Aliment Pharmacol Ther , vol.21 , pp. 363-371
    • Hanauer, S.1    Sandborn, W.J.2    Persson, A.3    Persson, T.4
  • 24
    • 0141963352 scopus 로고    scopus 로고
    • Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn’s disease
    • COI: 1:CAS:528:DC%2BD3sXlsVelsb0%3D, PID: 15017504
    • Mantzaris GJ, Petraki K, Sfakianakis M, et al. Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn’s disease. Clin Gastroenterol Hepatol. 2003;1:122–128.
    • (2003) Clin Gastroenterol Hepatol , vol.1 , pp. 122-128
    • Mantzaris, G.J.1    Petraki, K.2    Sfakianakis, M.3
  • 25
    • 20844432689 scopus 로고    scopus 로고
    • Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn’s disease
    • COI: 1:CAS:528:DC%2BD2MXit1alsLs%3D, PID: 15704045
    • Schoon EJ, Bollani S, Mills PR, et al. Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn’s disease. Clin Gastroenterol Hepatol. 2005;3:113–121.
    • (2005) Clin Gastroenterol Hepatol , vol.3 , pp. 113-121
    • Schoon, E.J.1    Bollani, S.2    Mills, P.R.3
  • 26
    • 35548982154 scopus 로고    scopus 로고
    • Maintenance treatment with budesonide 6 mg versus 9 mg once daily in patients with Crohn’s disease in remission
    • PID: 17954953
    • de Jong DJ, Bac DJ, Tan G, et al. Maintenance treatment with budesonide 6 mg versus 9 mg once daily in patients with Crohn’s disease in remission. Neth J Med. 2007;65:339–345.
    • (2007) Neth J Med , vol.65 , pp. 339-345
    • de Jong, D.J.1    Bac, D.J.2    Tan, G.3
  • 27
    • 0035128511 scopus 로고    scopus 로고
    • Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn’s disease
    • COI: 1:CAS:528:DC%2BD3MXhtFKnsrg%3D, PID: 11156638
    • Cortot A, Colombel JF, Rutgeerts P, et al. Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn’s disease. Gut. 2001;48:186–190.
    • (2001) Gut , vol.48 , pp. 186-190
    • Cortot, A.1    Colombel, J.F.2    Rutgeerts, P.3
  • 28
    • 60349125534 scopus 로고    scopus 로고
    • Oral budesonide for maintenance of remission of Crohn’s disease: a pooled safety analysis
    • COI: 1:CAS:528:DC%2BD1MXktFGrsb0%3D, PID: 19035972
    • Lichtenstein GR, Bengtsson B, Hapten-White L, Rutgeerts P. Oral budesonide for maintenance of remission of Crohn’s disease: a pooled safety analysis. Aliment Pharmacol Ther. 2009;29:643–653.
    • (2009) Aliment Pharmacol Ther , vol.29 , pp. 643-653
    • Lichtenstein, G.R.1    Bengtsson, B.2    Hapten-White, L.3    Rutgeerts, P.4
  • 30
    • 0028878830 scopus 로고
    • Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver
    • PID: 7720517
    • Jönsson G, Åström A, Andersson P. Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver. Drug Metab Dispos. 1995;23:137–142.
    • (1995) Drug Metab Dispos , vol.23 , pp. 137-142
    • Jönsson, G.1    Åström, A.2    Andersson, P.3
  • 32
    • 77953525114 scopus 로고    scopus 로고
    • New drug delivery systems in inflammatory bowel disease: MMX™ and tailored delivery to the gut
    • COI: 1:CAS:528:DC%2BC3cXmvFCnu70%3D, PID: 20353384
    • Fiorino G, Fries W, De La Rue SA, Malesci AC, Repici A, Danese S. New drug delivery systems in inflammatory bowel disease: MMX™ and tailored delivery to the gut. Curr Med Chem. 2010;17:1851–1857.
    • (2010) Curr Med Chem , vol.17 , pp. 1851-1857
    • Fiorino, G.1    Fries, W.2    De La Rue, S.A.3    Malesci, A.C.4    Repici, A.5    Danese, S.6
  • 33
    • 33748648599 scopus 로고    scopus 로고
    • Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study
    • PID: 16984503
    • D’Haens G, Hommes D, Engels L, et al. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study. Aliment Pharmacol Ther. 2006;24:1087–1097.
    • (2006) Aliment Pharmacol Ther , vol.24 , pp. 1087-1097
    • D’Haens, G.1    Hommes, D.2    Engels, L.3
  • 34
    • 33846242590 scopus 로고    scopus 로고
    • Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis
    • COI: 1:CAS:528:DC%2BD2sXitVCmsbs%3D, PID: 17234558
    • Lichtenstein GR, Kamm MA, Boddu P, et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2007;5:95–102.
    • (2007) Clin Gastroenterol Hepatol , vol.5 , pp. 95-102
    • Lichtenstein, G.R.1    Kamm, M.A.2    Boddu, P.3
  • 35
    • 33846213645 scopus 로고    scopus 로고
    • Once-daily, high-concentration MMX mesalamine in active ulcerative colitis
    • COI: 1:CAS:528:DC%2BD2sXit1aqsL0%3D, PID: 17241860
    • Kamm MA, Sandborn WJ, Gassull M, et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology. 2007;132:66–75.
    • (2007) Gastroenterology , vol.132 , pp. 66-75
    • Kamm, M.A.1    Sandborn, W.J.2    Gassull, M.3
  • 36
    • 46349099233 scopus 로고    scopus 로고
    • Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis
    • COI: 1:CAS:528:DC%2BD1cXoslemtrk%3D, PID: 18272546
    • Kamm MA, Lichtenstein GR, Sandborn WJ, et al. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut. 2008;57:893–902.
    • (2008) Gut , vol.57 , pp. 893-902
    • Kamm, M.A.1    Lichtenstein, G.R.2    Sandborn, W.J.3
  • 38
    • 33644928374 scopus 로고    scopus 로고
    • Gastrointestinal transit, release and plasma pharmacokinetics of a new oral budesonide formulation
    • COI: 1:CAS:528:DC%2BD28Xnt1ylsg%3D%3D, PID: 16390349
    • Brunner M, Ziegler S, Di Stefano AF, et al. Gastrointestinal transit, release and plasma pharmacokinetics of a new oral budesonide formulation. Br J Clin Pharmacol. 2006;61:31–38.
    • (2006) Br J Clin Pharmacol , vol.61 , pp. 31-38
    • Brunner, M.1    Ziegler, S.2    Di Stefano, A.F.3
  • 39
    • 0037441282 scopus 로고    scopus 로고
    • A pharmacoscintigraphic evaluation of oral budesonide given as controlled-release (Entocort) capsules
    • PID: 12622761
    • Edsbäcker S, Bengtsson B, Larsson P, et al. A pharmacoscintigraphic evaluation of oral budesonide given as controlled-release (Entocort) capsules. Aliment Pharmacol Ther. 2003;17:525–536.
    • (2003) Aliment Pharmacol Ther , vol.17 , pp. 525-536
    • Edsbäcker, S.1    Bengtsson, B.2    Larsson, P.3
  • 40
    • 0035181699 scopus 로고    scopus 로고
    • Effect of food on the pharmacokinetics of budesonide controlled ileal release capsules in patients with active Crohn’s disease
    • COI: 1:CAS:528:DC%2BD3MXotFCrtQ%3D%3D, PID: 11136277
    • Lundin P, Naber T, Nilsson M, Edsbäcker S. Effect of food on the pharmacokinetics of budesonide controlled ileal release capsules in patients with active Crohn’s disease. Aliment Pharmacol Ther. 2001;15:45–51.
    • (2001) Aliment Pharmacol Ther , vol.15 , pp. 45-51
    • Lundin, P.1    Naber, T.2    Nilsson, M.3    Edsbäcker, S.4
  • 41
    • 4644264048 scopus 로고    scopus 로고
    • Evaluation of oral budesonide in the treatment of active distal ulcerative colitis
    • COI: 1:CAS:528:DC%2BD2cXovF2ktbs%3D
    • Kolkman JJ, Mollmann HW, Mollmann AC, et al. Evaluation of oral budesonide in the treatment of active distal ulcerative colitis. Drugs Today (Barc). 2004;40:589–601.
    • (2004) Drugs Today (Barc) , vol.40 , pp. 589-601
    • Kolkman, J.J.1    Mollmann, H.W.2    Mollmann, A.C.3
  • 43
    • 84878375674 scopus 로고    scopus 로고
    • Bioavailability profile of Uceris MMX extended-release tablets compared with Entocort EC capsules in healthy volunteers
    • COI: 1:CAS:528:DC%2BC3sXns1Gjtro%3D, PID: 23569029
    • Nicholls A, Harris-Collazo R, Huang M, Hardiman Y, Jones R, Moro L. Bioavailability profile of Uceris MMX extended-release tablets compared with Entocort EC capsules in healthy volunteers. J Int Med Res. 2013;41:386–394.
    • (2013) J Int Med Res , vol.41 , pp. 386-394
    • Nicholls, A.1    Harris-Collazo, R.2    Huang, M.3    Hardiman, Y.4    Jones, R.5    Moro, L.6
  • 44
    • 0038121959 scopus 로고    scopus 로고
    • Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis
    • COI: 1:CAS:528:DC%2BD3sXlvFaisr4%3D, PID: 12830002
    • Hempfling W, Grunhage F, Dilger K, Reichel C, Beuers U, Sauerbruch T. Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. Hepatology. 2003;38:196–202.
    • (2003) Hepatology , vol.38 , pp. 196-202
    • Hempfling, W.1    Grunhage, F.2    Dilger, K.3    Reichel, C.4    Beuers, U.5    Sauerbruch, T.6
  • 45
    • 33644810639 scopus 로고    scopus 로고
    • Multidrug resistance 1 genotype and disposition of budesonide in early primary biliary cirrhosis
    • COI: 1:CAS:528:DC%2BD28XkslWitbs%3D, PID: 16584389
    • Dilger K, Cascorbi I, Grunhage F, Hohenester S, Sauerbruch T, Beuers U. Multidrug resistance 1 genotype and disposition of budesonide in early primary biliary cirrhosis. Liver Int. 2006;26:285–290.
    • (2006) Liver Int , vol.26 , pp. 285-290
    • Dilger, K.1    Cascorbi, I.2    Grunhage, F.3    Hohenester, S.4    Sauerbruch, T.5    Beuers, U.6
  • 46
    • 0141619279 scopus 로고    scopus 로고
    • Glucocorticoid resistance in inflammatory bowel disease
    • COI: 1:CAS:528:DC%2BD3sXotFOhsb4%3D, PID: 12967327
    • Farrell RJ, Kelleher D. Glucocorticoid resistance in inflammatory bowel disease. J Endocrinol. 2003;178:339–346.
    • (2003) J Endocrinol , vol.178 , pp. 339-346
    • Farrell, R.J.1    Kelleher, D.2
  • 47
    • 84921893654 scopus 로고    scopus 로고
    • Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies
    • COI: 1:CAS:528:DC%2BC2MXhvV2nurg%3D, PID: 25588902
    • Sandborn WJ, Danese S, D’Haens G, et al. Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies. Aliment Pharmacol Ther. 2015;41:409–418.
    • (2015) Aliment Pharmacol Ther , vol.41 , pp. 409-418
    • Sandborn, W.J.1    Danese, S.2    D’Haens, G.3
  • 48
    • 84973552519 scopus 로고    scopus 로고
    • Induction of remission with oral budesonide MMXVR (9 mg) tablets in patients with mild to moderate, active ulcerative colitis: a multicenter, open-label efficacy and safety study [Abstract]
    • Travis S, Ballard ED. Induction of remission with oral budesonide MMXVR (9 mg) tablets in patients with mild to moderate, active ulcerative colitis: a multicenter, open-label efficacy and safety study [Abstract]. Inflamm Bowel Dis. 2011;17:S20.
    • (2011) Inflamm Bowel Dis , vol.17 , pp. S20
    • Travis, S.1    Ballard, E.D.2
  • 49
    • 0027997229 scopus 로고
    • A comparison of budesonide with prednisolone for active Crohn’s disease
    • COI: 1:STN:280:DyaK2czlvFGntw%3D%3D, PID: 8078530
    • Rutgeerts P, Löfberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn’s disease. N Engl J Med. 1994;331:842–845.
    • (1994) N Engl J Med , vol.331 , pp. 842-845
    • Rutgeerts, P.1    Löfberg, R.2    Malchow, H.3
  • 50
    • 57249103566 scopus 로고    scopus 로고
    • Direct health care costs of Crohn’s disease and ulcerative colitis in United States children and adults
    • PID: 18854185
    • Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn’s disease and ulcerative colitis in United States children and adults. Gastroenterology. 2008;135:1907–1913.
    • (2008) Gastroenterology , vol.135 , pp. 1907-1913
    • Kappelman, M.D.1    Rifas-Shiman, S.L.2    Porter, C.Q.3
  • 51
    • 84871640598 scopus 로고    scopus 로고
    • Direct health care insurer and out-of-pocket expenditures of inflammatory bowel disease: evidence from a US national survey
    • PID: 22790905
    • Gunnarsson C, Chen J, Rizzo JA, Ladapo JA, Lofland JH. Direct health care insurer and out-of-pocket expenditures of inflammatory bowel disease: evidence from a US national survey. Dig Dis Sci. 2012;57:3080–3091.
    • (2012) Dig Dis Sci , vol.57 , pp. 3080-3091
    • Gunnarsson, C.1    Chen, J.2    Rizzo, J.A.3    Ladapo, J.A.4    Lofland, J.H.5
  • 52
    • 79955076079 scopus 로고    scopus 로고
    • Cost effectiveness of treatments for inflammatory bowel disease
    • PID: 21271748
    • Bodger K. Cost effectiveness of treatments for inflammatory bowel disease. Pharmacoeconomics. 2011;29:387–401.
    • (2011) Pharmacoeconomics , vol.29 , pp. 387-401
    • Bodger, K.1
  • 53
    • 84898853173 scopus 로고    scopus 로고
    • Case-control study of factors that trigger inflammatory bowel disease flares
    • COI: 1:CAS:528:DC%2BC2cXhsVSltL7E, PID: 24764669
    • Feagins LA, Iqbal R, Spechler SJ. Case-control study of factors that trigger inflammatory bowel disease flares. World J Gastroenterol. 2014;20:4329–4334.
    • (2014) World J Gastroenterol , vol.20 , pp. 4329-4334
    • Feagins, L.A.1    Iqbal, R.2    Spechler, S.J.3
  • 54
    • 0034798909 scopus 로고    scopus 로고
    • Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis
    • COI: 1:STN:280:DC%2BD3MnjvVWruw%3D%3D, PID: 11693328
    • Kane SV, Cohen RD, Aikens JE, Hanauer SB. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol. 2001;96:2929–2933.
    • (2001) Am J Gastroenterol , vol.96 , pp. 2929-2933
    • Kane, S.V.1    Cohen, R.D.2    Aikens, J.E.3    Hanauer, S.B.4
  • 55
    • 39549091909 scopus 로고    scopus 로고
    • The challenge of compliance and persistence: focus on ulcerative colitis
    • PID: 18240888
    • Kane SV, Brixner D, Rubin DT, Sewitch MJ. The challenge of compliance and persistence: focus on ulcerative colitis. J Manag Care Pharm. 2008;14:s2–s12.
    • (2008) J Manag Care Pharm , vol.14 , pp. s2-s12
    • Kane, S.V.1    Brixner, D.2    Rubin, D.T.3    Sewitch, M.J.4
  • 56
    • 33644995445 scopus 로고    scopus 로고
    • Systematic review: adherence issues in the treatment of ulcerative colitis
    • COI: 1:CAS:528:DC%2BD28XjslWgur8%3D, PID: 16480396
    • Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2006;23:577–585.
    • (2006) Aliment Pharmacol Ther , vol.23 , pp. 577-585
    • Kane, S.V.1
  • 57
    • 84866504286 scopus 로고    scopus 로고
    • Association between oral 5-ASA adherence and health care utilization and costs among patients with active ulcerative colitis
    • PID: 23006789
    • Mitra D, Hodgkins P, Yen L, Davis KL, Cohen RD. Association between oral 5-ASA adherence and health care utilization and costs among patients with active ulcerative colitis. BMC Gastroenterol. 2012;12:132.
    • (2012) BMC Gastroenterol , vol.12 , pp. 132
    • Mitra, D.1    Hodgkins, P.2    Yen, L.3    Davis, K.L.4    Cohen, R.D.5
  • 59
    • 0141961614 scopus 로고    scopus 로고
    • A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis
    • COI: 1:CAS:528:DC%2BD3sXlsVeltLo%3D, PID: 15017487
    • Kane S, Huo D, Magnanti K. A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clin Gastroenterol Hepatol. 2003;1:170–173.
    • (2003) Clin Gastroenterol Hepatol , vol.1 , pp. 170-173
    • Kane, S.1    Huo, D.2    Magnanti, K.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.